Kyle Gano sold $9.2M of Neurocrine Biosciences (NBIX)

Executed Jan 15 2025, disclosed Jan 17 2025, 2 days later.

Value, as filed

$9.2M

65,000 sh across 2 lots

Executed

Jan 15 2025

the trade date, as filed

Disclosed

Jan 17 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

KG Kyle Gano Chief Executive Officer profile →

Kyle Gano (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $4.8M of NBIX (36,400 sh across 2 lots, as filed), executed Jan 16.

The name

NBIX Neurocrine Biosciences, Inc. NBIX · Healthcare · 59 filings in 24 months ticker →

Healthcare · Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunolog…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Kyle Gano in NBIX

NBIXSALE Neurocrine Biosciences, Inc. $4.8M
36,400 sh across 2 lots
Exec Jan 16
Filed Jan 20 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $299K
2,558 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $116K
980 sh × $118.39
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $236K
1,541 sh × $152.87
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET